Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
12.88
+0.15 (1.18%)
Feb 24, 2026, 4:00 PM EST - Market closed

Tango Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,7353321,010639958-
Market Cap Growth
395.35%-67.13%57.94%-33.25%--
Enterprise Value
1,61776689287461-
Last Close Price
12.883.099.907.2510.9411.44
PS Ratio
26.087.8927.6425.7225.86-
PB Ratio
8.981.663.992.562.78-
P/TBV Ratio
10.841.663.992.562.78-
EV/Sales Ratio
24.311.8118.8711.5312.45-
Debt / Equity Ratio
0.220.180.150.170.000.20
Debt / FCF Ratio
-----0.11
Net Debt / Equity Ratio
-0.74-1.11-1.18-1.30-1.40-4.73
Net Debt / EBITDA Ratio
1.091.552.672.978.443.54
Net Debt / FCF Ratio
0.801.672.492.787.88-2.64
Asset Turnover
0.240.120.090.050.110.06
Quick Ratio
8.296.767.336.6311.984.70
Current Ratio
8.886.987.546.7612.104.73
Return on Equity (ROE)
-51.65%-57.58%-40.49%-36.41%-30.38%-223.51%
Return on Assets (ROA)
-24.52%-25.31%-17.01%-14.82%-10.28%-24.81%
Return on Capital Employed (ROCE)
-57.60%-52.30%-32.00%-29.20%-12.70%-31.40%
Earnings Yield
-5.79%-39.26%-10.08%-16.92%-6.08%-
FCF Yield
-8.46%-39.85%-11.84%-18.27%-6.41%-
Buyback Yield / Dilution
-2.50%-15.50%-7.69%-41.40%-94.50%-255.37%
Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q